NCT00214877View on ClinicalTrials.gov

Methylene Blue for Cognitive Dysfunction in Bipolar Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 30, 2003

Study Completion Date

October 31, 2007

Conditions
Bipolar Disorder
Interventions
DRUG

Methylene Blue

Trial Locations (2)

B3H-2E2

CDHA- QE II Health Sciences Centre, Halifax

L8N 3K7

St. Joseph's Healthcare, Hamilton

All Listed Sponsors
collaborator

Stanley Medical Research Institute

OTHER

lead

Nova Scotia Health Authority

OTHER

NCT00214877 - Methylene Blue for Cognitive Dysfunction in Bipolar Disorder | Biotech Hunter | Biotech Hunter